252 related articles for article (PubMed ID: 32415712)
21. Benzamide capped peptidomimetics as non-ATP competitive inhibitors of CDK2 using the REPLACE strategy.
Premnath PN; Craig SN; Liu S; McInnes C
Bioorg Med Chem Lett; 2016 Aug; 26(15):3754-60. PubMed ID: 27297568
[TBL] [Abstract][Full Text] [Related]
22. Dinaciclib Induces Anaphase Catastrophe in Lung Cancer Cells via Inhibition of Cyclin-Dependent Kinases 1 and 2.
Danilov AV; Hu S; Orr B; Godek K; Mustachio LM; Sekula D; Liu X; Kawakami M; Johnson FM; Compton DA; Freemantle SJ; Dmitrovsky E
Mol Cancer Ther; 2016 Nov; 15(11):2758-2766. PubMed ID: 27550941
[TBL] [Abstract][Full Text] [Related]
23. Molecular dynamics simulations on the inhibition of cyclin-dependent kinases 2 and 5 in the presence of activators.
Zhang B; Tan VB; Lim KM; Tay TE
J Comput Aided Mol Des; 2006 Jun; 20(6):395-404. PubMed ID: 17054019
[TBL] [Abstract][Full Text] [Related]
24. Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition.
Au-Yeung G; Lang F; Azar WJ; Mitchell C; Jarman KE; Lackovic K; Aziz D; Cullinane C; Pearson RB; Mileshkin L; Rischin D; Karst AM; Drapkin R; Etemadmoghadam D; Bowtell DD
Clin Cancer Res; 2017 Apr; 23(7):1862-1874. PubMed ID: 27663592
[No Abstract] [Full Text] [Related]
25. Novel Pyrazolo[3,4-d]pyrimidines as Potential Cytotoxic Agents: Design, Synthesis, Molecular Docking and CDK2 Inhibition.
Maher M; Kassab AE; Zaher AF; Mahmoud Z
Anticancer Agents Med Chem; 2019; 19(11):1368-1381. PubMed ID: 31038080
[TBL] [Abstract][Full Text] [Related]
26. The anticancer activity of the substituted pyridone-annelated isoindigo (5'-Cl) involves G0/G1 cell cycle arrest and inactivation of CDKs in the promyelocytic leukemia cell line HL-60.
Saleh AM; Aljada A; El-Abadelah MM; Taha MO; Sabri SS; Zahra JA; Aziz MA
Cell Physiol Biochem; 2015; 35(5):1943-57. PubMed ID: 25870953
[TBL] [Abstract][Full Text] [Related]
27. Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells.
Caldon CE; Sergio CM; Kang J; Muthukaruppan A; Boersma MN; Stone A; Barraclough J; Lee CS; Black MA; Miller LD; Gee JM; Nicholson RI; Sutherland RL; Print CG; Musgrove EA
Mol Cancer Ther; 2012 Jul; 11(7):1488-99. PubMed ID: 22564725
[TBL] [Abstract][Full Text] [Related]
28. A Precision Medicine Drug Discovery Pipeline Identifies Combined CDK2 and 9 Inhibition as a Novel Therapeutic Strategy in Colorectal Cancer.
Somarelli JA; Roghani RS; Moghaddam AS; Thomas BC; Rupprecht G; Ware KE; Altunel E; Mantyh JB; Kim SY; McCall SJ; Shen X; Mantyh CR; Hsu DS
Mol Cancer Ther; 2020 Dec; 19(12):2516-2527. PubMed ID: 33158998
[TBL] [Abstract][Full Text] [Related]
29. AZ703, an imidazo[1,2-a]pyridine inhibitor of cyclin-dependent kinases 1 and 2, induces E2F-1-dependent apoptosis enhanced by depletion of cyclin-dependent kinase 9.
Cai D; Byth KF; Shapiro GI
Cancer Res; 2006 Jan; 66(1):435-44. PubMed ID: 16397259
[TBL] [Abstract][Full Text] [Related]
30. Molecular basis for the specificity of p27 toward cyclin-dependent kinases that regulate cell division.
Lacy ER; Wang Y; Post J; Nourse A; Webb W; Mapelli M; Musacchio A; Siuzdak G; Kriwacki RW
J Mol Biol; 2005 Jun; 349(4):764-73. PubMed ID: 15890360
[TBL] [Abstract][Full Text] [Related]
31. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.
Meijer L; Borgne A; Mulner O; Chong JP; Blow JJ; Inagaki N; Inagaki M; Delcros JG; Moulinoux JP
Eur J Biochem; 1997 Jan; 243(1-2):527-36. PubMed ID: 9030781
[TBL] [Abstract][Full Text] [Related]
32. AZD5438-PROTAC: A selective CDK2 degrader that protects against cisplatin- and noise-induced hearing loss.
Hati S; Zallocchi M; Hazlitt R; Li Y; Vijayakumar S; Min J; Rankovic Z; Lovas S; Zuo J
Eur J Med Chem; 2021 Dec; 226():113849. PubMed ID: 34560429
[TBL] [Abstract][Full Text] [Related]
33. Involvement of cyclin-dependent kinases in axotomy-induced retinal ganglion cell death.
Lefèvre K; Clarke PG; Danthe EE; Castagné V
J Comp Neurol; 2002 May; 447(1):72-81. PubMed ID: 11967896
[TBL] [Abstract][Full Text] [Related]
34. Cyclin-dependent kinase 2 is an ideal target for ovary tumors with elevated cyclin E1 expression.
Yang L; Fang D; Chen H; Lu Y; Dong Z; Ding HF; Jing Q; Su SB; Huang S
Oncotarget; 2015 Aug; 6(25):20801-12. PubMed ID: 26204491
[TBL] [Abstract][Full Text] [Related]
35. Critical reanalysis of the methods that discriminate the activity of CDK2 from CDK1.
Sakurikar N; Eastman A
Cell Cycle; 2016 May; 15(9):1184-8. PubMed ID: 26986210
[TBL] [Abstract][Full Text] [Related]
36. Discovery of 3,6-disubstituted pyridazines as a novel class of anticancer agents targeting cyclin-dependent kinase 2: synthesis, biological evaluation and in silico insights.
Sabt A; Eldehna WM; Al-Warhi T; Alotaibi OJ; Elaasser MM; Suliman H; Abdel-Aziz HA
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1616-1630. PubMed ID: 32781872
[TBL] [Abstract][Full Text] [Related]
37. Imidazo[1,2-c]pyrimidin-5(6H)-one inhibitors of CDK2: Synthesis, kinase inhibition and co-crystal structure.
Jansa J; Jorda R; Škerlová J; Pachl P; Peřina M; Řezníčková E; Heger T; Gucký T; Řezáčová P; Lyčka A; Kryštof V
Eur J Med Chem; 2021 Apr; 216():113309. PubMed ID: 33711765
[TBL] [Abstract][Full Text] [Related]
38. Discovery of a novel class of 2-aminopyrimidines as CDK1 and CDK2 inhibitors.
Lee J; Kim KH; Jeong S
Bioorg Med Chem Lett; 2011 Jul; 21(14):4203-5. PubMed ID: 21684737
[TBL] [Abstract][Full Text] [Related]
39. Development of allosteric and selective CDK2 inhibitors for contraception with negative cooperativity to cyclin binding.
Faber EB; Sun L; Tang J; Roberts E; Ganeshkumar S; Wang N; Rasmussen D; Majumdar A; Hirsch LE; John K; Yang A; Khalid H; Hawkinson JE; Levinson NM; Chennathukuzhi V; Harki DA; Schönbrunn E; Georg GI
Nat Commun; 2023 Jun; 14(1):3213. PubMed ID: 37270540
[TBL] [Abstract][Full Text] [Related]
40. Discovery of novel CDK inhibitors via scaffold hopping from CAN508.
Jing L; Tang Y; Xiao Z
Bioorg Med Chem Lett; 2018 May; 28(8):1386-1391. PubMed ID: 29550093
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]